MAPK7 and cancer: To target this pathway, numerous ATP-competitive inhibitors targeting ERK5 catalytic activity have been developed (Wang and Tournier, 2006; Drew et al., 2012; Lochhead et al., 2012; Nithianandarajah-Jones et al., 2012; Le et al., 2013; Le et al., 2014; Cook et al., 2020) and evaluated for their potential in treating cancer and inflammatory diseases (Drew et al., 2012; Cook et al., 2020).